MedTrace Logo

Time in rANge vs. Time in nOrmal Glycemia for Better Glycemic Control

NCT07376850 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2026-01-29

No results posted yet for this study

Summary

The TANGO study is a 12-month study involving 120 children and adolescents with Type 1 Diabetes (T1D) across the Czech Republic, Israel, and Poland who use automated insulin delivery (AID) systems.

Currently, the global standard for diabetes management is "Time in Range" (TIR), which aims to keep blood sugar levels between 70-180 mg/dL. However, newer technologies like AID systems may now allow for a tighter, more physiological goal called "Time in Normal Glycemia" (TING), which targets a range of 70-140 mg/dL.

This study will randomly assign participants to follow either the standard TIR target or the tighter TING target to see if the narrower range improves overall blood sugar control and HbA1c without increasing the risk of hypoglycemia, family stress, or daily treatment burden.

By comparing these two approaches, researchers hope to determine if clinical guidelines should be updated to reflect a more precise glucose target for children and adolescents worldwide

Conditions

  • Diabetes
  • Diabetes (DM)
  • Diabetes Type 1

Interventions

OTHER

Structured Diabetes Education

A comprehensive standardized guideline will be provided to recruiting physicians from all centers, including the points below: 1. Understanding CGM data and trend interpretation 2. TIR or TING concepts according to randomization, target range, consequences of hypoglycemia and hyperglycemia 3. Recognizing and management of hypoglycemia 4. Recognizing and management of hyperglycemia 5. Setting and adjusting of glycemic targets, alarms in CGM and insulin pumps, and insulin doses based on randomisation 6. Emotional coping strategies and involving family support

OTHER

Automated Insulin Delivery (AID) System Adjustment

For the TING group, CGM hyperglycemia target settings will be lowered by at-least 10% from the baseline values. The extent of the adjustment will be at the discretion of the attending physician

Sponsors & Collaborators

  • Schneider Children's Medical Center, Israel

    collaborator OTHER

  • Medical University of Warsaw

    collaborator OTHER

  • University Hospital, Motol

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
5 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-31
Primary Completion
2026-05-31
Completion
2026-06-30

Countries

  • Czechia
  • Israel
  • Poland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07376850 on ClinicalTrials.gov